 Before we begin, I would like to remind you that during todays call and QA session, we will be making forward-looking statements. Risks and uncertainties that contribute to the uncertain nature of these forward-looking statements include the effects of the COVID-19 pandemic on our business and financial condition; the expectation that Aimmune will need additional funds to finance its operations; Aimmunes dependence on the success of PALFORZIA; Aimmunes ability to build a commercial field organization and distribution network; the degree of acceptance of PALFORZIA among physicians, patients, healthcare payers, patient advocacy groups and the general medical community; Aimmunes ability to obtain favorable coverage and reimbursement from third-party payers for PALFORZIA; Aimmunes ability to implement and comply with the REMS for PALFORZIA; Aimmunes or any of its collaborative partners ability to initiate andor complete clinical trials; the unpredictability of the regulatory process; the possibility that Aimmunes or any of its collaborative partners clinical trials will not be successful; the reliance on third parties for the manufacture of PALFORZIA and our product candidates; possible regulatory developments in the United States and foreign countries; and Aimmunes ability to attract and retain senior management personnel. 